NLRP3 inflammasome inhibition protects function of
MDSC-IL13s. Cultured WT MDSC-IL13s were treated as indicated
with reagents to inhibit inflammasome induction or myeloid maturation 1
hour before LPS plus ATP inflammasome induction: glyburide (100
µM), MCC950 (10 µM), ICTA2 (200 µg/ml), BHB (200
µM), A-438079 (25 µM), and ruxolitinib (1 µM). One
hour after ATP stimulation, cultures were assayed as indicated. (A)
Culture supernatants were assessed for IL-1β. (B) Harvested MDSCs
were counted and plated for CFSE suppression assay at a 1:1 ratio with
responding CD25-depleted whole T cells (WTCs); data represent frequency
of CD8+ T cells undergoing ≥1 division. (C) MDSCs
were washed, counted, and assayed for cell-associated arginase-1
activity. (A-C) In vitro data represent 3 replicates per condition and 2
independent experiments. (D) Kaplan-Meier survival curve for B6 >
Balb/c GVHD animals given MDSC-IL13s (M13) and/or the NLRP3-specific
inhibitor MCC950 (MCC) (50 mg/kg intraperitoneally) every other day
starting at day −1 for 3 weeks. WTCs vs M13, P
< .001; WTCs vs MCC, P = .0055; WTCs vs M13
plus MCC, P < .0001; M13 vs MCC,
P = .0152; M13 vs M13 plus MCC,
P = .4291; MCC vs MCC plus M13,
P = .1226. Data represent combination of 3
independent experiments, n = 30 per group. (E) Kaplan-Meier
survival curve for B6 > Balb/c GVHD animals given MDSC-IL13 (M13)
and/or the NLRP3-specific inhibitor ICTA. WTCs vs M13,
P = .0028; WTCs vs ICTA2, P
= .0128; WTCs vs M13 plus ICTA, P = .0001;
M13 or ICTA vs M13 plus ICTA, P = not significant.
Data represent a single experiment, n = 10 per group.
**P < .01,
****P < .0001.